Tabuk Pharmaceuticals Manufacturing Company

tabukpharmaceuticals.com

Tabuk Pharmaceuticals develops, manufactures, markets and distributes branded generic pharmaceuticals and under-licensed products globally, with a strong focus on the Middle East and North Africa region.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

FDA ACCEPTS DUPIXENT® (DUPILUMAB) FOR PRIORITY REVIEW IN ADULTS WITH PRURIGO NODULARIS

Regeneron Pharmaceuticals, Inc. | May 31, 2022

news image

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® Medical (dupilumab) to treat adults with prurigo nodularis, a chronic skin disease that causes extreme itch and inflammatory skin lesions. The target action date for the FDA decision is September 30, 2022. The sBLA is supported by data from two pivotal Phase 3 trials evaluating the e...

Read More

PHARMACY MARKET, PHARMA TECH

MTTI OBTAINS FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG (IND) FOR HÜRTHLE CELL THYROID CANCER

Molecular Targeting Technologies, Inc | December 09, 2022

news image

Molecular Targeting Technologies, Inc. a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the allowance of an Investigational New Drug application by the U.S. Food and Drug Administration. It is now waiting for Institutional Review Board approval. Once approved by IRB, it will enable a Phase I/II clinical study of the Safety, Dosimetry and Efficacy of EBTATE in adult patients with metastatic, radioactive iodine non-responsive Hürthle...

Read More

Business Insights, PHARMACY MARKET

THERAPEUTICSMD ANNOUNCES DEFINITIVE AGREEMENTS TO LICENSE ITS PRODUCTS TO MAYNE PHARMA

TherapeuticsMD, Inc. | December 05, 2022

news image

TherapeuticsMD, Inc. an innovative, leading women’s healthcare company, announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products. At clo...

Read More

PHARMA GIANT ROCHE GETS US GO-AHEAD FOR COVID-19 ANTIBODY TEST

The guardian | May 03, 2020

news image

Swiss drug maker Roche Holding AG says it has received emergency use approval from the US Food and Drug Administration (FDA) for an antibody test to help determine if people have ever been infected with the coronavirus. Governments, businesses and individuals are seeking such blood tests to help them learn more about who may have had the disease, who may have some immunity and to potentially craft strategies to end lockdowns that have battered global economies. Roche had previously pledged to ma...

Read More
news image

Business Insights

FDA ACCEPTS DUPIXENT® (DUPILUMAB) FOR PRIORITY REVIEW IN ADULTS WITH PRURIGO NODULARIS

Regeneron Pharmaceuticals, Inc. | May 31, 2022

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® Medical (dupilumab) to treat adults with prurigo nodularis, a chronic skin disease that causes extreme itch and inflammatory skin lesions. The target action date for the FDA decision is September 30, 2022. The sBLA is supported by data from two pivotal Phase 3 trials evaluating the e...

Read More
news image

PHARMACY MARKET, PHARMA TECH

MTTI OBTAINS FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG (IND) FOR HÜRTHLE CELL THYROID CANCER

Molecular Targeting Technologies, Inc | December 09, 2022

Molecular Targeting Technologies, Inc. a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the allowance of an Investigational New Drug application by the U.S. Food and Drug Administration. It is now waiting for Institutional Review Board approval. Once approved by IRB, it will enable a Phase I/II clinical study of the Safety, Dosimetry and Efficacy of EBTATE in adult patients with metastatic, radioactive iodine non-responsive Hürthle...

Read More
news image

Business Insights, PHARMACY MARKET

THERAPEUTICSMD ANNOUNCES DEFINITIVE AGREEMENTS TO LICENSE ITS PRODUCTS TO MAYNE PHARMA

TherapeuticsMD, Inc. | December 05, 2022

TherapeuticsMD, Inc. an innovative, leading women’s healthcare company, announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products. At clo...

Read More
news image

PHARMA GIANT ROCHE GETS US GO-AHEAD FOR COVID-19 ANTIBODY TEST

The guardian | May 03, 2020

Swiss drug maker Roche Holding AG says it has received emergency use approval from the US Food and Drug Administration (FDA) for an antibody test to help determine if people have ever been infected with the coronavirus. Governments, businesses and individuals are seeking such blood tests to help them learn more about who may have had the disease, who may have some immunity and to potentially craft strategies to end lockdowns that have battered global economies. Roche had previously pledged to ma...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us